Indexé dans
- Ouvrir la porte J
- Genamics JournalSeek
- CiteFactor
- RechercheRef
- Université Hamdard
- EBSCO AZ
- NSD - Centre norvégien de données de recherche
- OCLC - WorldCat
- Publions
- Fondation genevoise pour la formation et la recherche médicales
- Pub européen
- Google Scholar
Liens utiles
Partager cette page
Dépliant de journal
Revues en libre accès
- Agriculture et aquaculture
- Alimentation et nutrition
- Biochimie
- Bioinformatique et biologie des systèmes
- Business & Management
- Chimie
- Génétique et biologie moléculaire
- Immunologie & Microbiologie
- Ingénierie
- La science des matériaux
- Neurosciences & Psychologie
- Science générale
- Sciences cliniques
- Sciences environnementales
- Sciences médicales
- Sciences pharmaceutiques
- Sciences vétérinaires
- Soins infirmiers et soins de santé
Abstrait
Triple Negative Breast Cancer – An Overview
Kartik Aysola, Akshata Desai, Crystal Welch, Jingyao Xu, Yunlong Qin, Vaishali Reddy, Roland Matthews, Charlotte Owens, Joel Okoli, Derrick J Beech, Chandrika J Piyathilake, Shyam P Reddy and Veena N Rao
Triple Negative Breast Cancer (TNBC) is a heterogeneous disease that based on immunohistochemistry (IHC) is estrogen receptor (ER) negative, progesterone receptor (PR) negative and human epidermal growth factor receptor 2 (HER2) negative. TNBC is typically observed in young AA women and Hispanic women who carry a mutation in the BRCA1 gene. TNBC is characterized by a distinct molecular profile, aggressive nature and lack of targeted therapies. The purpose of this article is to review the current and future novel signalling pathways as therapeutic approaches to TNBC. Recent Identification of a new BRCA1 trafficking pathway holds promise in the future for the development of targeted therapies for TNBC.